Try a new search

Format these results:

Searched for:



Total Results:


A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS

McMeeking A; Borkowsky W; Klesius PH; Bonk S; Holzman RS; Lawrence HS
Cryptosporidial infection causes severe diarrheal disease in patients with AIDS. Fourteen patients with AIDS and symptomatic cryptosporidiosis were treated with a specific bovine dialyzable leukocyte extract (immune DLE) prepared from lymph node lymphocytes of calves immunized with cryptosporidia or a nonspecific (nonimmune) DLE prepared from nonimmunized calves. Six of 7 patients given immune DLE gained weight and had a decrease in bowel movement frequency, with eradication of oocysts from stool in 5 patients. Six of 7 patients given nonimmune DLE showed no decrease in bowel movement and 4, no clearing of oocytes from stool; 5 continued to lose weight. Subsequently, 5 of these 7 were treated with immune DLE; 4 had a decrease in bowel movement frequency and significant weight gain, with eradication of oocytes from stool in 2 patients. Immune DLE produces sustained symptomatic improvement in patients with AIDS and active cryptosporidiosis, but lack of an appropriate cryptosporidial antigen allows only postulation that an augmentation of cellular immunity to Cryptosporidium parvum induced by immune DLE resulted in the microbiologic and clinical improvement observed
PMID: 2404072
ISSN: 0022-1899
CID: 14566

Don't forget AIDS at any age [Letter]

McMeeking, A A; Schwartz, L; Garay, S
PMID: 2592727
ISSN: 0002-8614
CID: 582632

Mammary tuberculosis [Case Report]

McMeeking, A A; Gonzalez, R; Hanna, B
PMID: 2733893
ISSN: 0028-7628
CID: 582842

Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome

Cohn, J A; McMeeking, A; Cohen, W; Jacobs, J; Holzman, R S
PURPOSE/OBJECTIVE:This study was designed to measure response rates and survival in patients with acquired immunodeficiency syndrome (AIDS) and suspected Toxoplasma encephalitis treated empirically and in AIDS patients treated for biopsy-proven toxoplasmosis. PATIENTS AND METHODS/METHODS:AIDS patients identified at Bellevue Hospital between August 1985 and May 1986, who had abnormal computed tomographic scans of the brain and who received empiric treatment for toxoplasmosis, constitute the empirically treated cohort. A cohort with biopsy-proven toxoplasmosis was identified from Bellevue Hospital neuropathology records spanning 1981 through 1986. Patient records were reviewed with a standardized data form, and tomograms were evaluated by neuroradiologists unaware of the identity of the scans. Survival analysis was performed by the product limit method. RESULTS:Of 38 empirically treated patients, 26 responded clinically and radiographically within four weeks of initiation of therapy. Four of nine patients who underwent biopsy responded to treatment. There was no difference in these response rates (68% versus 44%, p = 0.24). The median survival of the empirically treated responders, from first diagnosis of AIDS to last follow-up, was 422 days. Among the 30 responders, five patients discontinued therapy and four of them had relapses. No relapses occurred in the 25 patients who continued full-dose therapy indefinitely (p = 0.0004). Sixteen of 30 patients (53%) receiving continuous therapy developed toxicity, which required a change in medication. There was no difference in the survival of patients who continued to receive sulfadiazine and pyrimethamine compared with those in whom clindamycin was substituted for sulfadiazine (median, 311 days versus 422 days, p = 0.25). CONCLUSION/CONCLUSIONS:A policy of empiric treatment of suspected Toxoplasma encephalitis is satisfactory, and patients who respond to such therapy and continue to take full therapeutic doses of anti-Toxoplasma drugs have relatively long survivals.
PMID: 2712059
ISSN: 0002-9343
CID: 3697722


Mcmeeking, A; Borkowsky, W; Klesius, PH; Bonk, S; Haynes, TB; Holzman, RS; Lawrence, HS
ISSN: 0009-9279
CID: 31519

Group G streptococcal bacteremia and parenteral drug abusers [Letter]

McMeeking AA; Holzman RS
PMID: 3343538
ISSN: 0022-1899
CID: 63329

Group B streptococcal osteomyelitis in an adult [Case Report]

McMeeking AA; Holzman R; Desiderio D; Hanna B
PMID: 3309742
ISSN: 0028-7628
CID: 63356

Chloroquine and Fansidar prophylaxis--a reply [Letter]

McMeeking, A A
PMID: 3553354
ISSN: 0022-1899
CID: 583592

Report of a wound infection caused by Vibrio parahaemolyticus and Vibrio vulnificus [Case Report]

McMeeking, A A; Codd, W J; Hanna, B A
The present case describes a foot wound caused by a clam shell from which both Vibrio parahaemolyticus and Vibrio vulnificus were recovered. Although extraintestinal infections associated with Vibrio parahaemolyticus have been reported previously, the simultaneous isolation of two marine vibrios from our case suggests that these organisms may coexist in mixed infections from a common source.
PMID: 2875824
ISSN: 0732-8893
CID: 3692492

Disinfection for HTLV-III: halogenated soaps [Letter]

Schuster, M; Cohn, J; McMeeking, A
PMID: 3007790
ISSN: 0098-7484
CID: 3692542